Novel Regimens in COVID-19 Treatment

Conditions

Corona Virus Infection, COVID

Brief summary

Nitazoxanide has been shown to have a clinical efficacy against severe acute respiratory syndrome coronavirus 2; ivermectin has also demonstrated a remarkable experimental efficacy with a potential to be used for Coronavirus disease 2019.

Detailed description

Nitazoxanide has been shown to have a clinical efficacy against severe acute respiratory syndrome coronavirus; ivermectin has also demonstrated a remarkable experimental efficacy with a potential to be used for Coronavirus disease 2019. Some studies demonstrated the efficacy of combined regimen of nitazoxanide and azithromycin or ivermectin and chloroquine.

Tania A. Smith, Carlos Hoyo‐Vadillo, Akosua Agyeman Adom, Liliana Favari-Perozzi, Silke Gastine et al. (20 authors)

Trials2022-07-227 citations

10.1186/s13063-022-06533-0

Nitazoxanide superiority to placebo to treat moderate COVID-19 - A Pilot prove of concept randomized double-blind clinical trial.

Blum VF, Cimerman S, Hunter JR, Tierno P, Lacerda A, Soeiro A, Cardoso F, Bellei NC, Maricato J, Mantovani N, Vassao M, Dias D, Galinskas J, Janini LMR, Santos-Oliveira JR, Da-Cruz AM, Diaz RS.

2021-06-2749 citations

10.1016/j.eclinm.2021.100981

Interventions

DRUGNitazoxanide

Nitazoxanide

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

No

Inclusion criteria

* Patients with COVID-19 infection

Exclusion criteria

* Allergy or contraindication to the drugs.

Design outcomes

Primary

Measure	Time frame	Description
Number of patients with virological cure	6 months	the number of patients with virological cure

Countries

Egypt

Contacts

Primary ContactSherief Abd-Elsalam, ass. prof.

sheriefabdelsalam@yahoo.com00201147773440

Outcome results

None listed